131 iodine for the initial treatment of thyroid cancer;L'iode 131 lors du traitement initial du cancer thyroidien

Annales d'Endocrinologie

Volumn 58, Issue 3, 1997, Pages 197-203

  Delisle, M J ^a   Clerc, J ^b  

^a INSTITUT JEAN GODINOT   (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 131; THYROTROPIN;

HUMAN; HUMAN CELL; HUMAN TISSUE; PROGNOSIS; RADIATION PROTECTION; REVIEW; RISK ASSESSMENT; THYROID CANCER; THYROID SCINTISCANNING; THYROIDECTOMY; THYROTROPIN BLOOD LEVEL; TREATMENT INDICATION;

COMBINED MODALITY THERAPY; HUMANS; IODINE RADIOISOTOPES; METHODS; POSTOPERATIVE PERIOD; RADIATION PROTECTION; RADIOTHERAPY DOSAGE; THYROID NEOPLASMS;

EID: 0030925820     PISSN: 00034266     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. BAL C, PADHY AK, JANA S et al. Prospective Randomized Clinical Trial to Evaluate the Optimal Dose of 1311 for Remnant Ablation in Patients with Differentied Thyroid Carcinoma. Cancer 1996, 77 : 2574-80.
2. BARRINGTON SF, KETTLE AG, O'DOHERTY M et al. Radiation dose rates from patients receiving iodine-131 the rapy for carcinoma of the thyroid. Eur J Nucl Med 1996, 23 : 123-30.
3. BENUA RS, CICALE NR, SONENBERG M et al. Relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer. Am J Rœntgenol 1962, 87 : 171.
4. CADY B, Rossi R. An expanded view of risk-group definition in differentiated thyroid carcinoma. Surgery 1988, 104 : 947-53.
5. CANNONI M, DEMARD F. Les Nodules Thyroidiens du Diagnostic à la Chirurgie Arnette Ed., Paris 1995, p. 271.
6. COMTOIS R, THERIAULT C, DELVECCHIO P. Assessment of the efficacy of iodine 131 for thyroid ablation. J Nucl Med 1993, 34 : 1927.
7. CULVER CM, DWORKIN HJ. Radiation Safety Considerations for Post-Iodine-131 Thyroid Cancer Therapy. J Nucl Med 1992 ; 33 : 1402-5.
8. DAVIS NL, GORDON M, GERMANN E et al. Efficacy of 1311 Ablation Following Thyroidectomy in Patients With Invasive Follicular Thyroid Cancer. Am J Surg 1992, 165 : 472-5.
9. DELISLE MJ, GIBOLD C, SCHLUMBERGER M. Treatment of Thyroid Cancer with 131-I in Europe. Eur J Nucl Med 1990 : 16 : S 70.
10. DELISLE MJ, SCHVARTZ C, THEOBALD S et al. Les cancers de la thyroïde. Intérêt d'un registre régional de 627 patients diagnostiqués, traités et suivis par une équipe multidisciplinaire. Ann Endocrinol (Paris) 1996, 57 : 41-9.
11. DELISLE MJ, SCHVARTZ C. Iode 131 et cancers thyroïdiens différenciés. Ann Endocrinol (Paris) 1996, 57 : 186-93.
12. DELISLE MJ. La radioprotection des malades, de leur entourage et de leur environnement lors de l'utilisation thé rapeutique des sources radioactives non scellées (Personnel médical exclu). In : Radioprotection et Santé Publique. Ed ; ACOMEN. Lyon, 1993, pp. 151-160.
13. DEVATHAIRE F, SCHLUMBERGER M, DELISLE MJ et al. Leukemias and cancers following 1311 administration for thyroid cancer, (à paraître).
14. DOTTORINI ME, LOMUSCIO G, MAZZUCCHELLI L et al. Assessment of Female Fertility and Carcinogenesis After Iodine-131 Therapy for Differentiated Thyroid Carcinoma. J Nucl Med 1995, 36 : 21-7.
15. EDMONDS CJ, SMITH T. The long-term hazards of the treatment of thyroid cancer with radioiodine. Br J Radiol 1986, 59 : 45.
16. GALLOWAY RJ, SMALLRIDGE RC. Imaging in thyroid cancer. Thyroid Cancer II 1996, 25 : 93-113.
17. GIBOLD C, DELISLE MJ, LIEHN JC. Usefulness of bone anatomic landmarking in 131 iodine scan for the diagnosis of metastases of differentiated thyroid carcinoma. In : Schmidt HAE, van der School JB, eds. Nuclear medicine. Stuttgart New York : Schattauer 1991 ; 46-8.
18. GREENSPAN FS. Moderate Hypothyroidism in Preparation for Whole Body 1311 Scinscans and Thyroglobulin Testing. Thyroid. 1996, 6, 493.
19. GUIMARAES V, DE GROOT LJ. Moderate Hypothyroidism in Preparation for Whole Body 1311 Scintiscans and Thyroglobulin Testing. Thyroid 1996, 6 : 69-73.
20. HALL P, BOICE J, BERG G et al. Leukemia incidence after iodine exposure. Lancet 1992, 340 : 1
21. MANNEQUIN P, LIEHN JC. DELISLE MJ. Multifactorial Analysis of Survival in Thyroid Cancer. Pitfalls of Applying the Results of Published Studies to Another Population. Cancer 1986 ; 58 : 1749-55.
22. HAY ID, BERGSTRALH EJ, GOELLNER JR, EBERSOLD JR, GRANT CS. Predicting outcome in papillary thyroid carcinoma : Development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery 1993 ; 114 : 1050-8.
23. HAY ID. Prognostic Factors in Thyroid Carcinoma. Thyroid Today 1989 ; 11 : 1-9.
24. MAXON HR. The Role of 1311 in the Treatment of Thyroid Cancer. Thyroid Today 1993 ; 2 : 1-9.
25. MAXON III HR, ENGLARO EE, THOMAS SR et al Radioiodine-131 Therapy for Well-Differentiated Thyroid Cancer. A Quantitative Radiation Dosimetric Approach : Outcome and validation in 85 Patients. J Nucl Med 1992, 33 : 1132-6.
26. MAZZAFERRI EL, JUIANG SM. Long-term Impact of Initial Surgical and Medical Therapy on Papillary and Follicular Thyroid Cancer. Am J Nucl 1994 ; 97 : 418-28.
27. MCHENRY C, JAROSZ H, DAVIS M et al. Selective post-operative radioactive iodine treatment of thyroid carcinoma. Br J Surg 1990, 77 : 110-3.
28. NOGUCHI S, YAMASHITA H. MURAKAMI N et al. Small Carcinomas of the Thyroid A Long-term Follow-up of 867 Patients. Arch Surg 1996, 131 : 187-91.
29. O'CONNELL ME, FLOWER MA. HINTON PJ et al. Radiation dose assessment in radioiodine therapy. Dose-response relationships in differentiated thyroid carcinoma using quantitative scanning and PET. Radiother. Oncol. 1993, 28 : 16-26.
30. PACINI F, GASPERI M, FUGAZZDA L et al. Testicular function in patients with differentiated thyroid carcinoma treated with radioiodine. J Nucl Med 1994, 35 : 1418.
31. PARK HM, PERKINS OW, EDMONDSON JW et al. Influence of Diagnostic Radioiodines on the Uptake of Ablative Dose of Iodine-131. Thyroid 1994, 4 : 49-54.
32. SAMAAN NA, SCHULTZ PN, HICKEY RC et al. The Results of Various Modalities of Treatment of Well Differentiated Thyroid Carcinoma : A Retrospective Review of 1599 Patients. J Clin Endocrinol Metab 1992, 75 : 714-20.
33. SAMUEL AM, RAJASHEKHARRAO B. Radioiodine Therapy for Well-Differentiated Thyroid Cancer : A Quantitative Dosimetric Evaluation for Remnant Thyroid Ablation After Surgery. J Nucl Med 1994, 35 : 1944-50.
34. SARKAR SD, BEIERWALTES WH, GILL SP et al. Subsequent fertility and birth histories of children and adolescents treated with 1311 for thyroid cancer. J Nucl Med 1976, 17 : 460.
35. SCHLUMBERGER M, CHELLETON C, DE VATHAIRE F et al. Radioactive Iodine treatment and External Radiotherapy for Lung and Bone Metastases from Thyroid Carcinome. J Nucl Med 1996, 37 : 598-605.
36. SCHLUMBERGER M, DE VATHAIRE F, CECCARELLI C, DELISLE MJ et al. Exposure to Radioactive Iodine-131 for Scintigraphy or Therapy Dœs Not Preclude Pregnancy in Thyroid Cancer Patients. J Nucl Med 1996, 37 : 606-12.
37. SCHLUMBERGER M, TUBIANA M, DE VATHAIRE F et al. Long-Term Results of Treatment of 283 Patients with Lung and Bone Metastases from Differentiated Thyroid Carcinoma. J Clin Endocrinol Metab 1986, 63 : 960-7.
38. SCHVARTZ C, THEOBALD S, DELISLE MJ. Distant metastases in differentiated thyroid carcinoma. Multivariate analysis of prognostic variables. Thyroid 1995, 5 : S
39. SCOTT AM, MACAPINLAC HM, ZHANG J et al. Image Registration of SPECT and CT Images Using an External Fiduciary Band and Three-Dimensional Surface Fitting in Metastatic Thyroid Cancer. J Nucl Med 1995 ; 36 : 100-3.
40. SINGER PA, COOPER DS, DANIELS GH, LADENSON PW et al Treatment Guidelines for Patients With Thyroid Nodules and Well-Differentiated Thyroid Cancer. Arch Intern Med 1996, 156 : 2165-72.
41. SOLOMON BL, WARTOFSKY L, BURMAN KD. Current Trends in the Management of Well Differentiated Papillary Thyroid Carcinoma. J Clin Endocrinol Metab 1996, 81 : 333-9.
42. TENENBAUM F, SCHLUMBERGER M, BONNIN F et al. Usefulness of technetium-99m hydroxymethylene disphosphonate scans in localizing bone metastases of differentiated thyroid carcinoma. Eur J Nucl Med 1993 ; 20 : 1168-74
43. VAN DE VELDE CJH, HAMMING JF, GOSLINGS BM et al. Report of the Consensus Development Conference on the Management of Differentiated Thyroid Cancer in the Netherlands. Eur J Cancer Clin Oncol 1988, 24 : 287-92.